These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
250 related items for PubMed ID: 28883275
1. [Successful management of intraperitoneal bleeding with platelet apheresis and von Willebrand factor supplementation in a patient with essential thrombocythemia and acquired von Willebrand syndrome]. Ueki T, Takeshige K, Sumi M, Ueno M, Ichikawa N, Kobayashi H. Rinsho Ketsueki; 2017; 58(8):922-926. PubMed ID: 28883275 [Abstract] [Full Text] [Related]
5. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera. Michiels JJ, Berneman Z, Schroyens W, Finazzi G, Budde U, van Vliet HH. Semin Thromb Hemost; 2006 Sep; 32(6):589-604. PubMed ID: 16977569 [Abstract] [Full Text] [Related]
8. The platelet function analyzer (PFA-100) may not be suitable for monitoring the therapeutic efficiency of von willebrand concentrate in type III von willebrand disease. Meskal A, Vertessen F, Van der Planken M, Berneman ZN. Ann Hematol; 1999 Sep; 78(9):426-30. PubMed ID: 10525831 [Abstract] [Full Text] [Related]
9. The course of acquired von Willebrand syndrome during pregnancy among patients with essential thrombocytosis. Rottenstreich A, Kleinstern G, Amsalem H, Kalish Y. J Thromb Thrombolysis; 2018 Oct; 46(3):304-309. PubMed ID: 29654448 [Abstract] [Full Text] [Related]
11. Qualitative and quantitative modifications of von Willebrand factor in patients with essential thrombocythemia and controlled platelet count. Lancellotti S, Dragani A, Ranalli P, Petrucci G, Basso M, Tartaglione R, Rocca B, De Cristofaro R. J Thromb Haemost; 2015 Jul; 13(7):1226-37. PubMed ID: 25876231 [Abstract] [Full Text] [Related]
13. Evaluation of a rapid von Willebrand factor activity latex immuno assay for monitoring of patients with von Willebrand disease (VWD) receiving DDAVP or VWF replacement therapy. Vinayagam S, Simons LR, Chowdary P, Thurlow P, Brooks SV, Riddell AF. Haemophilia; 2014 Jul; 20(4):e304-10. PubMed ID: 24758424 [Abstract] [Full Text] [Related]
14. Acquired type 3-like von Willebrand syndrome preceded full-blown systemic lupus erythematosus. Niiya M, Niiya K, Takazawa Y, Hayashi Y, Tanio Y, Kushiro M, Tanimizu M, Hasegawa H, Tanimoto M. Blood Coagul Fibrinolysis; 2002 Jun; 13(4):361-5. PubMed ID: 12032403 [Abstract] [Full Text] [Related]
15. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3. Michiels JJ, van Vliet HH, Berneman Z, Gadisseur A, van der Planken M, Schroyens W, van der Velden A, Budde U. Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493 [Abstract] [Full Text] [Related]
16. Case report: Peri-procedural hydroxyurea helps minimize bleeding in patients with Essential Thrombocythemia associated with acquired von Willebrand syndrome. Kogan L, Price R, Kotchetkov R. Front Oncol; 2024 Jan; 14():1326209. PubMed ID: 38361779 [Abstract] [Full Text] [Related]
18. Essential thrombocythaemia in a teenage girl resulting in acquired von Willebrand syndrome with joint haemorrhage and menorrhagia. Rolf N, Suttorp M, Budde U, Siegert G, Knoefler R. Thromb Haemost; 2010 Jun; 103(6):1272-4. PubMed ID: 20352170 [No Abstract] [Full Text] [Related]